行情

CEMI

CEMI

Chembio诊断
NASDAQ

实时行情|Nasdaq Last Sale

4.337
-0.183
-4.04%
交易中 14:24 11/19 EST
开盘
4.570
昨收
4.520
最高
4.690
最低
4.280
成交量
2.25万
成交额
--
52周最高
7.90
52周最低
3.950
市值
7,618.87万
市盈率(TTM)
-5.6111
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CEMI 新闻

  • Edited Transcript of CEMI earnings conference call or presentation 7-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.3天前
  • Chembio Diagnostics to Participate in Upcoming Investor Conferences
  • GlobeNewswire.4天前
  • Imagine Owning Chembio Diagnostics (NASDAQ:CEMI) And Wondering If The 35% Share Price Slide Is Justified
  • Simply Wall St..11/12 11:43
  • Chembio Diagnostics, Inc. (CEMI) CEO John Sperzel on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/10 11:59

更多

所属板块

制药
+0.39%
制药与医学研究
+0.77%

热门股票

名称
价格
涨跌幅

CEMI 简况

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
展开

Webull提供Chembio Diagnostics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。